Alisertib联合诱导化疗治疗初诊高危急性髓系白血病:单臂2期试验
这项单臂2期试验纳入39例初诊高危急性髓系白血病患者,在7+3诱导化疗(阿糖胞苷持续输注+伊达比星)后于第8-15天加用口服alisertib 30 mg每日两次。复合缓解率为64%(两阶段95%CI 48-79),51%达完全缓解,13%达中性粒细胞或血小板未完全恢复的完全缓解;未观察到治疗相关死亡。
要点
- 复合缓解率64%,完全缓解率51%,支持alisertib联合方案值得进入随机试验。
- 常见3-4级不良事件为发热性中性粒细胞减少41%、中性粒细胞减少31%、血小板减少33%。
- 研究中未发生治疗相关死亡,联合方案安全性可接受。
核心结论
- Alisertib联合诱导化疗在初诊高危急性髓系白血病患者中显示有活性且安全。
- 研究达到推进至未来随机试验的标准。
研究设计与样本
- 单臂2期试验,自美国Dana-Farber/Harvard癌症中心招募患者,注册号NCT02560025,已完成入组。
- 2015年12月31日至2017年8月1日共入组39例符合条件的高危初诊急性髓系白血病患者,分析按方案进行。
主要发现
- 39例中19例(49%)为继发性急性髓系白血病,3例(8%)为治疗相关急性髓系白血病。
- 诱导中期33例(85%)出现骨髓再生障碍,6例(15%)接受再诱导。
- 复合缓解率64%(两阶段95%CI 48-79),其中20例(51%)达完全缓解,5例(13%)达中性粒细胞或血小板未完全恢复的完全缓解。
- 常见3-4级不良事件:发热性中性粒细胞减少16例(41%)、中性粒细胞减少12例(31%)、血小板减少13例(33%)、贫血11例(28%)、厌食9例(23%)、口腔黏膜炎4例(10%)。
关键数值与推荐
- 诱导方案:阿糖胞苷100 mg/m2/天持续输注第1-7天,伊达比星12 mg/m2/天静脉推注第1-3天。
- alisertib 30 mg口服每日两次,第8-15天给药。
- 巩固治疗最多4周期(阿糖胞苷+alisertib),alisertib维持治疗12个月。
- 主要终点为完全缓解与中性粒细胞或血小板未完全恢复的完全缓解的复合比例。
临床怎么用
- 对初诊高危急性髓系白血病可在7+3诱导后序贯alisertib,并密切监测骨髓抑制与感染。
- 该方案目前限于试验背景,需待随机试验进一步验证后再考虑常规应用。
局限性
- 单臂设计、样本量39例、单中心招募,缺乏随机对照,结论需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Increased aurora A kinase (AAK) expression occurs in acute myeloid leukaemia; AAK inhibition is a promising therapeutic target in this disease. We therefore aimed to assess the activity of alisertib combined with 7 + 3 induction chemotherapy in previously untreated patients with high-risk acute myeloid leukaemia. METHODS: We did a single-arm, phase 2 trial of patients recruited from the Dana-Farber/Harvard Cancer Center in the USA. Eligible patients had previously untreated acute myeloid leukaemia, an Eastern Cooperative Oncology Group performance status of 0-2, and were at high risk of disease as defined by the presence of an adverse-risk karyotype, the presence of secondary acute myeloid leukaemia arising from previous myelodysplastic syndrome or myeloproliferative neoplasm, the presence of therapy-related acute myeloid leukaemia, or being 65 years or older. Enrolled patients received 7 + 3 induction chemotherapy of continuous infusion of cytarabine (100 mg/m2 per day on days 1-7) and intravenous bolus of idarubicin (12 mg/m2 per day on days 1-3). Oral alisertib (30 mg) was given twice per day on days 8-15. Patients could receive up to four consolidation cycles with cytarabine and alisertib, and alisertib maintenance for 12 months. The primary endpoint was a composite including the proportion of patients achieving complete remission and those with a complete remission with incomplete neutrophil or platelet count recovery. Analyses were per-protocol. This study is registered with Clinicaltrials.gov, number NCT02560025, and has completed enrolment. FINDINGS: Between Dec 31, 2015, and Aug 1, 2017, we enrolled a total of 39 eligible patients. 19 (49%) of 39 patients had secondary acute myeloid leukaemia and three (8%) had therapy-related acute myeloid leukaemia. At mid-induction, 33 (85%) of 39 patients showed marrow aplasia, six (15%) received re-induction. The median follow-up was 13·7 months (IQR 12·7-14·4). Composite remission was 64% (two-stage 95% CI 48-79), with 20 (51%) of 39 patients achieving complete remission and five (13%) achieving complete remission with incomplete neutrophil or platelet count recovery. The most common grade 3 or 4 adverse events included febrile neutropenia (16 [41%] of 39), neutropenia (12 [31%]), thrombocytopenia (13 [33%]), anaemia (11 [28%]), anorexia (nine [23%]), and oral mucositis (four [10%]). No treatment-related deaths were observed. INTERPRETATION: These results suggest that alisertib combined with induction chemotherapy is active and safe in previously untreated patients with high-risk acute myeloid leukaemia. This study met criteria to move forward to a future randomised trial. FUNDING: Millennium Pharmaceuticals.
引用
- Brunner AM, Blonquist TM, DeAngelo DJ, et al. Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2019. PMID: 31837959. doi:10.1016/S2352-3026(19)30203-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。